Avantor Inc(AVTR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:35 AM ET (Korea 10/30 20:35)
Full metrics table
| Index | - | P/E | 33.62 | EPS (ttm) | 0.5 | Insider Own | 3.07% | Shs Outstand | 677.7M | Perf Week | -2.74% |
| Market Cap | 11.28B | Forward P/E | 18.76 | EPS next Y | 8.78% | Insider Trans | 0.17% | Shs Float | 655.6M | Perf Month | 10.83% |
| Enterprise Value | 14.50B | PEG | 7.25 | EPS next Q | 0.22 | Inst Own | 102.53% | Short Float | 5.28% | Perf Quarter | 21.04% |
| Income | 0.34B | P/S | 1.7 | EPS this Y | -9.21% | Inst Trans | 2.68% | Short Ratio | 3.69 | Perf Half Y | 105.93% |
| Sales | 6.64B | P/B | 1.94 | EPS next 5Y | 2.59% | ROA | 2.89% | Short Interest | 34.65M | Perf YTD | 45.55% |
| Book/sh | 8.61 | P/C | 24.3 | EPS past 3/5Y | - | ROE | 5.91% | 52W High | -4.41% ($17.45) | Perf Year | 44.04% |
| Cash/sh | 0.69 | P/FCF | 25.69 | Sales past 3/5Y | -4.46% 0.49% | ROIC | 3.56% | 52W Low | 129.59% ($7.26) | Perf 3Y | -6.45% |
| Dividend Est. | - | EV/EBITDA | 14.98 | EPS Y/Y TTM | 517.17% | Gross Margin | 30.45% | Volatility(W/M) | 3.1% 3.26% | Perf 5Y | -58.69% |
| Dividend TTM | - | EV/Sales | 2.19 | Sales Y/Y TTM | 0.92% | Oper. Margin | 8.27% | ATR (14) | 0.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.27 | EPS Q/Q | 128.61% | Profit Margin | 5.08% | RSI (14) | 59.99 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.89 | Sales Q/Q | 4.59% | SMA20 | 2.76% ($16.23) | Beta | 0.97 | Target Price | $17.35 |
| Payout | - | Debt/Eq | 0.63 | Earnings | 2026/10/28 | SMA50 | 7.93% ($15.45) | Rel Volume | 1.2 | Prev Close | $16.69 |
| Employees | 13500 | LT Debt/Eq | 0.63 | EPS/Sales Surpr. | 5.26% 3.37% | SMA200 | 49.25% ($11.18) | Avg Volume(3M) | 9.38M | Price | $16.68 |
| IPO | 2019/5/17 | Option/Short | Yes/Yes | Trades | 38745 | Volume | 11,218,173 | Change | -0.06% |
🧪 This U.S. company supplies materials, consumables, and services to the life sciences and advanced technology sectors. It provides chemicals, materials, and consumables used in laboratory, research, and production applications, as well as bioprocessing materials, and offers laboratory services and distribution. As a medical instruments name, its performance is tied to bio and research demand along with recurring consumables revenue.
Over the past 1 year, on the higher side
4% below its 1-year high.
Traded about as much as usual. That is 120% of its average volume.
AVTR makes money exceptionally well
Of every $100 in sales, $8.27 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -9.2% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,876. Peers typically go for $1,901. Compared with its own 4-year average, it is 64% cheaper now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -58.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 102.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #11 of 51 in the industry
Based on market cap of $11B.
FAQ
What kind of company is AVTR?
AVTR belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of AVTR?
The market cap of AVTR is approximately $11.3B, ranking 862 within its sector.
What is the P/E ratio of AVTR?
AVTR has a P/E ratio of approximately 33.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AVTR?
AVTR has recorded a 52-week high of $17.45 and a low of $7.26.
